HGSI, CAT in big antibody pact

Human Genome Sciences announced that it will invest $67 million in a broad alliance with Cambridge Antibody Technology (LSE:CAT) to develop human antibodies.

HGSI will have rights to use CAT's phage display technology to develop an unlimited number of human antibodies for both therapeutic and diagnostic applications, and have rights to use and sell related research tools developed by CAT in a revenue sharing arrangement in addition to potential milestones and royalties on HGSI antibody products resulting from the collaboration. ...